Abstract
Checkpoint Inhibitor (CPI) therapy is standard of care in a range of tumor types but many patients fail to gain long term clinical benefit. Agonist antibodies targeting the T cell costimulatory receptor CD137 (4-1BB) have shown immune-stimulatory effects, but hepatotoxicity significantly hindered development. FS222, a novel tetravalent bispecific antibody, incorporates two CD137 binding sites in the Fc-region (Fcab) and anti-PD-L1 Fabs in a natural human IgG1 antibody with silenced FcyR activity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have